Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 197

Sort by

Sort Order Select

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Jiri Minarik, Ludek Pour, Tomas Jelinek, Ivan Spicka, Alexandra Jungova, Jakub Radocha, Petr Pavlicek, Tomas Pika, Martin Stork, Jan Straub, Vladimir Maisnar, Roman Hajek

Blood (2023) 142 (Supplement 1): 4733.

https://doi.org/10.1182/blood-2023-179299

Published: 2023

Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 4.

https://doi.org/10.1182/blood-2023-177546

Published: 2023

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

Anti-BCMA-CAR NK Cells Expressing Soluble TRAIL: Promising Therapeutic Approach for Multiple Myeloma in Combination with Bortezomib and γ-Secretase Inhibitors

Benjamin Motais, Sandra Charvátová, Matouš Hrdinka, Roman Hájek, Juli R. Bago

Blood (2022) 140 (Supplement 1): 12683–12684.

https://doi.org/10.1182/blood-2022-166167

Published: 2022

Journal Articles

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Roman Hajek, Henrik Sliwka, Martin Stork, Ivan Spicka, Tomas Jelinek, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Jan Soukup, Nolen Joy Perualila, Joris Diels, Michel van Speybroeck, Nichola Erler-Yates, João Mendes, Kai Strobel, Sébastien Wischlen, Maximilian Merz

Blood (2022) 140 (Supplement 1): 7200–7202.

https://doi.org/10.1182/blood-2022-159401

Published: 2022

Journal Articles

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Blood (2022) 140 (Supplement 1): 4420–4422.

https://doi.org/10.1182/blood-2022-165942

Published: 2022

Journal Articles

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Blood (2022) 140 (Supplement 1): 4409–4411.

https://doi.org/10.1182/blood-2022-156390

Published: 2022

Journal Articles

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Andrew Spencer, Maria Gavriatopoulou, Daniel Coriu, Sandra Basic - Kinda, Roman Hajek, Ankit Pahwa, Rebekah Taylor, Kristin Lehn, Roby Joehanes, Jeremy A. Ross, Carlos Hader

Blood (2022) 140 (Supplement 1): 12481–12482.

https://doi.org/10.1182/blood-2022-159677

Published: 2022

Journal Articles

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 9995–9997.

https://doi.org/10.1182/blood-2022-163092

Published: 2022

Journal Articles

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

Noemi Puig, Vania T.M. Hungria, Ajai Chari, Faith E. Davies, Gordon Cook, Roman Hájek, Kathryn E. Morgan, Jim Omel, Evangelos Terpos, Michael A. Thompson, Saad Usmani, Jorge Vela-Ojeda, Katja Weisel, Mira Armour, Kaili Ren, Dasha Cherepanov, Dawn Marie Stull, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 4269–4272.

https://doi.org/10.1182/blood-2022-163074

Published: 2022

Journal Articles

Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis

Zuzana Chyra, Morgan O'Keefe, Tereza Sevcikova, Roman Hajek, Kenneth C. Anderson, Sophia Adamia

Blood (2021) 138 (Supplement 1): 4719.

https://doi.org/10.1182/blood-2021-153532

Published: 2021

Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status

Pieter Sonneveld, Maria-Victoria Mateos, Pawel J. Robak, Fredrik H. Schjesvold, Roman Hajek, Paul G. Richardson, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, Meletios-Athanasios Dimopoulos

Blood (2021) 138 (Supplement 1): 4779.

https://doi.org/10.1182/blood-2021-146844

Published: 2021

Journal Articles

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis

Meletios-Athanasios Dimopoulos, Fredrik H. Schjesvold, María-Victoria Mateos, Pawel J. Robak, Roman Hájek, Paul G. Richardson, Jakob Lindberg, Marcus Thuresson, Kajsa Larsson, Pieter Sonneveld

Blood (2021) 138 (Supplement 1): 4780.

https://doi.org/10.1182/blood-2021-146994

Published: 2021

Journal Articles

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Tereza Popkova, Ludek Pour, Ivan Spicka, Jakub Radocha, Alexandra Jungova, Jiri Minarik, Tomas Jelinek, Petr Pavlicek, Marta Krejci, Jan Straub, Vladimir Maisnar, Tereza Dekojova, Tomas Pika, Jan Soukup, Lenka Capkova, Roman Hájek

Blood (2021) 138 (Supplement 1): 4894.

https://doi.org/10.1182/blood-2021-153978

Published: 2021

Journal Articles

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Blood (2021) 138 (Supplement 1): 3793.

https://doi.org/10.1182/blood-2021-146003

Published: 2021

Journal Articles

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Tomas Jelinek, Renata Bezděková, David Zihala, Tereza Sevcikova, Lenka Capkova, Petra Polackova, Martin Stork, Zdenka Knechtova, Ondrej Venglar, Artur Jurczyszyn, Jorge J. Castillo, Miroslav Penka, Jakub Radocha, Sabina Sevcikova, Ludek Pour, Lucie Rihova, Roman Hajek

Blood (2021) 138 (Supplement 1): 546.

https://doi.org/10.1182/blood-2021-151592

Published: 2021

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Tomas Jelinek, David Zihala, Tereza Sevcikova, Veronika Kapustova, Hana Sahinbegovic, Anjana Anilkumar Sithara, Tereza Popkova, Hana Plonkova, Lucie Broskevicova, Jan Vrana, Vladimir Zidlik, Martin Havel, Zdenek Koristek, Juli R. Bago, Michal Simicek, Roman Hajek

Blood (2021) 138 (Supplement 1): 2680.

https://doi.org/10.1182/blood-2021-150876

Published: 2021

Journal Articles

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Zuzana Chyra, Mehmet K. Samur, Anil Aktas-Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Ryosuke Shirasaki, Masood A. Shammas, Constantine S. Mitsiades, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2021-152121

Published: 2021

NARROW

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Comparison of Lenalidomide Based Triplets (IRD, KRD and DRD) in Relapsed and Refractory Multiple Myeloma in Routine Practice

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Anti-BCMA-CAR NK Cells Expressing Soluble TRAIL: Promising Therapeutic Approach for Multiple Myeloma in Combination with Bortezomib and γ-Secretase Inhibitors

Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years

Prevalence of t(11;14) Multiple Myeloma in Real-World Setting: Interim Analysis from the Medici Study

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed/Refractory Multiple Myeloma (RRMM) - Impact of Prior Treatments Analysis

Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in Czech Republic

Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study

Circulating Plasma Cells Are the Most Powerful Prognostic Marker in Transplant Ineligible Multiple Myeloma with 2% As a New Cut-Off for Primary Plasma Cell Leukemia

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only